Sone-214 — ~repack~

| Phase | Status | Key Milestones | |-------|--------|----------------| | | Completed 2022 (GLP tox, CMC) | IND submission to FDA (March 2023) | | Phase I (first‑in‑human, healthy volunteers) | Completed (Oct 2023) | • Single‑ascending dose (SAD) up to 150 mg – tolerable. • PK: Cmax at 2 h; half‑life ≈ 7 h; linear exposure 10‑150 mg. • PD: IFN‑β ↑ 3‑5‑fold at 50 mg; IL‑6 unchanged. • No serious adverse events (SAEs). | | Phase I/IIa (oncology – solid tumors) | Ongoing (as of Apr 2024) | • Open‑label, dose‑escalation (25‑100 mg PO daily) in patients with advanced melanoma, NSCLC, and pancreatic cancer. • Primary endpoint: safety/tolerability; secondary: ORR, PFS, immune‑gene signatures. | | Phase IIb (combination with anti‑PD‑1) | Planned for H2 2025 | • Multi‑center, randomized (SO‑214 + pembrolizumab vs. pembrolizumab alone) in refractory melanoma and head‑and‑neck SCC. | | Regulatory | IND active; fast‑track designation granted (FDA, Dec 2023) for “immunogenic tumor conversion”. | |

| Application | Rationale | Development status | |-------------|-----------|--------------------| | | STING activation amplifies antigen presentation and germinal‑center formation. SONE‑214’s oral route could allow “self‑adjuvanting” oral boosters. | Pre‑clinical proof‑of‑concept in mouse influenza vaccine (single oral dose → 2‑log reduction in viral load). | | Chronic viral infections (HBV, HCV, HIV latency reversal) | IFN‑β up‑regulation can suppress viral replication; STING activation may “shock” latent reservoirs. | In‑vitro latency reversal in HIV‑infected Jurkat cells; IND‑enabling toxicology for HBV underway. | | Auto‑immune modulation (e.g., SLE) | Low‑dose, biased STING agonism can re‑balance type I IFN pathways. | Early academic collaborations; no commercial program yet. | | Neurodegenerative disease (ALS, AD) | Emerging data suggest STING‑mediated clearance of cytosolic DNA from damaged mitochondria reduces neuroinflammation. | Proof‑of‑concept in SOD1‑G93A ALS mouse model (oral 10 mg/kg QD → delayed motor decline). | sone-214

Sone-214 is an emerging clinical candidate, with several clinical trials currently underway to evaluate its efficacy and safety in patients with advanced cancer. These trials, including an ongoing Phase 1 study and a Phase 2 trial in NSCLC, are designed to assess the safety, tolerability, and anti-tumor activity of Sone-214 when administered as a single agent or in combination with other anticancer agents. | Phase | Status | Key Milestones |

Early preclinical studies have demonstrated the efficacy of Sone-214 in inhibiting tumor growth and reducing metastasis in a range of orthotopic and xenograft cancer models. For example, in NSCLC (non-small cell lung cancer) models, Sone-214 has been shown to reduce tumor burden by >50% compared to control animals, while also demonstrating potent anti-metastatic activity. Similarly, studies in breast cancer models have demonstrated that Sone-214 suppresses the growth of tumors and reduces the number of lung metastases by >70% compared to control animals. • No serious adverse events (SAEs)